NATRNasdaqPharmaceutical PreparationsFiscal year ends December 31
NATURES SUNSHINE PRODUCTS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$12.55−0.09 (-0.71%)
Close on Oct 19, 2026
- Market cap
- $230.13M
- P/E (TTM)
- 12.4
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
72.4%−1.3 pts over 5 years
Operating margin
5.2%−0.4 pts over 5 years
Net margin
4.1%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +5.7% | +4.4% | +4.5% | +4.0% | |
| Gross profit | +7.1% | +5.1% | +4.1% | +3.8% | |
| Operating income | +23.1% | +15.0% | +2.9% | +6.0% | |
| Net income | +153.7% | – | – | – | |
| EPS, diluted | +165.0% | – | -0.2% | +3.2% | |
| Free cash flow | +101.3% | – | -2.5% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on assets | – | – | 7.8% | |
| Current ratio | 1.50 | 2.21 | 2.28 | |
| Net debt to EBITDA | – | -2.74× | – | |
| Interest coverage | 627.4× | 210.6× | 252.5× | |
| Inventory turnover | 2.1× | 2.1× | 2.1× | |
| Capex to revenue | 3.2% | 1.3% | 1.3% | |
| Diluted shares | 19M | 20M | 18M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Natures Sunshine Products generated $137.16M from operations and spent $114.64M on capital expenditure, dividends and share buybacks. 37% of that went back into the business.
Generated
$137.16M
Used
$114.64M
Capital expenditure$42.22M37%Dividends$19.86M17%Share buybacks$52.56M46%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
7of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero$19.52M
- Cash generatingOperating cash flow above zero$35.32M
- Return on assets improvedROA up on the prior year3.1% → 8.1%
- Earnings backed by cashOperating cash flow above net income$35.32M vs $19.52M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose2.44 → 2.28
- No dilutionShare count did not rise19M → 18M
- Gross margin improvedGross margin up on the prior year71.46% → 72.42%
- More efficientAsset turnover rose1.82 → 1.99